- Home
- AEVA vs PBYI Comparison
AEVA vs PBYI Comparison
Compare AEVA & PBYI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AEVA | PBYI |
|---|---|---|
| Founded | 2019 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Auto Parts:O.E.M. | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 600.2M | 263.4M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | AEVA | PBYI |
|---|---|---|
| Price | $13.08 | $6.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 4 | 1 |
| Target Price | ★ $26.50 | $7.00 |
| AVG Volume (30 Days) | ★ 2.0M | 378.0K |
| Earning Date | 11-05-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 59.87 |
| EPS | N/A | ★ 0.74 |
| Revenue | $15,154,000.00 | ★ $211,995,000.00 |
| Revenue This Year | $87.44 | N/A |
| Revenue Next Year | $70.13 | N/A |
| P/E Ratio | ★ N/A | $8.28 |
| Revenue Growth | ★ 89.90 | N/A |
| 52 Week Low | $2.52 | $2.58 |
| 52 Week High | $38.80 | $6.22 |
Technical Indicators
Market Signals| Indicator | AEVA | PBYI |
|---|---|---|
| Relative Strength Index (RSI) | 46.87 | 69.88 |
| Support Level | $12.83 | $5.81 |
| Resistance Level | $15.73 | $5.73 |
| Average True Range (ATR) | 1.23 | 0.24 |
| MACD | -0.14 | 0.05 |
| Stochastic Oscillator | 7.90 | 87.77 |
Price Performance
Historical ComparisonAbout AEVA Aeva Technologies Inc.
Aeva Technologies Inc through its Frequency Modulated Continuous Wave (FMCW) sensing technology, designs a 4D LiDAR-on-chip that, along with its proprietary software applications, has the potential to enable the adoption of LiDAR across broad applications from automated driving to consumer electronics, consumer health, industrial automation, and security application. The company operates in North America, EMEA, and Asia. The company derives the majority of its revenue from North America.
About PBYI Puma Biotechnology Inc
Puma Biotechnology Inc is a biopharmaceutical company that develops and commercializes inventive products to enhance cancer care and improve treatment outcomes for patients. It is currently commercializing NERLYNX, an oral version of neratinib, for the treatment of HER2-positive breast cancer. Also it develops alisertib. Alisertib is a selective, small-molecule inhibitor of aurora kinase A that is designed to disrupt mitosis resulting into apoptosis of rapidly proliferating tumor cells that are dependent on aurora kinase A.